PMC:7402624 / 41401-41757 JSONTXT

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T17","span":{"begin":214,"end":219},"obj":"Body_part"}],"attributes":[{"id":"A17","pred":"uberon_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/UBERON_0002542"}],"text":"To further investigate the relationship between immune responses and COVID-19 disease trajectory, we stratified the COVID-19 patients (n = 125) into eight different categories according to the NIH Ordinal Severity Scale ranging from COVID 1 (death) and COVID 2 (requiring maximal clinical intervention) to COVID 8 (at home with no required care) (Fig. 6A)."}

{"project":"LitCovid-PubTator","denotations":[{"id":"1481","span":{"begin":125,"end":133},"obj":"Species"},{"id":"1484","span":{"begin":69,"end":77},"obj":"Disease"},{"id":"1485","span":{"begin":116,"end":124},"obj":"Disease"},{"id":"1486","span":{"begin":233,"end":238},"obj":"Disease"},{"id":"1487","span":{"begin":242,"end":247},"obj":"Disease"},{"id":"1488","span":{"begin":253,"end":258},"obj":"Disease"},{"id":"1489","span":{"begin":306,"end":311},"obj":"Disease"}],"attributes":[{"id":"A1481","pred":"tao:has_database_id","subj":"1481","obj":"Tax:9606"},{"id":"A1484","pred":"tao:has_database_id","subj":"1484","obj":"MESH:C000657245"},{"id":"A1485","pred":"tao:has_database_id","subj":"1485","obj":"MESH:C000657245"},{"id":"A1486","pred":"tao:has_database_id","subj":"1486","obj":"MESH:C000657245"},{"id":"A1487","pred":"tao:has_database_id","subj":"1487","obj":"MESH:D003643"},{"id":"A1488","pred":"tao:has_database_id","subj":"1488","obj":"MESH:C000657245"},{"id":"A1489","pred":"tao:has_database_id","subj":"1489","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"To further investigate the relationship between immune responses and COVID-19 disease trajectory, we stratified the COVID-19 patients (n = 125) into eight different categories according to the NIH Ordinal Severity Scale ranging from COVID 1 (death) and COVID 2 (requiring maximal clinical intervention) to COVID 8 (at home with no required care) (Fig. 6A)."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T317","span":{"begin":69,"end":77},"obj":"Disease"},{"id":"T318","span":{"begin":116,"end":124},"obj":"Disease"}],"attributes":[{"id":"A317","pred":"mondo_id","subj":"T317","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A318","pred":"mondo_id","subj":"T318","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"To further investigate the relationship between immune responses and COVID-19 disease trajectory, we stratified the COVID-19 patients (n = 125) into eight different categories according to the NIH Ordinal Severity Scale ranging from COVID 1 (death) and COVID 2 (requiring maximal clinical intervention) to COVID 8 (at home with no required care) (Fig. 6A)."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T89","span":{"begin":48,"end":64},"obj":"http://purl.obolibrary.org/obo/GO_0006955"}],"text":"To further investigate the relationship between immune responses and COVID-19 disease trajectory, we stratified the COVID-19 patients (n = 125) into eight different categories according to the NIH Ordinal Severity Scale ranging from COVID 1 (death) and COVID 2 (requiring maximal clinical intervention) to COVID 8 (at home with no required care) (Fig. 6A)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T240","span":{"begin":0,"end":356},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"To further investigate the relationship between immune responses and COVID-19 disease trajectory, we stratified the COVID-19 patients (n = 125) into eight different categories according to the NIH Ordinal Severity Scale ranging from COVID 1 (death) and COVID 2 (requiring maximal clinical intervention) to COVID 8 (at home with no required care) (Fig. 6A)."}